(March 6, 2017) A team from University of Texas MD Anderson Cancer Center, including OCRFA Scientific Advisory Committee Member Dr. Robert Coleman, published a study in Journal of Clinical Oncology about the effect of hormonal therapy on a rare type of ovarian cancer. The use of hormone maintenance therapy (HMT) with low-grade serous carcinoma (LGSC), a subtype of epithelial ovarian or peritoneum cancer, was found to significantly improve both profession free survival and overall survival.
Research has shown that LGSC has a high rate of recurrence (approximately 70). Women who were treated with HMT after surgery and chemotherapy had an average progression-free survival of 64.9 months whereas women who were only observed after the same treatment of surgery and chemotherapy had a progression free survival rate of 26.4 months. The same groups of patients had an overall survival rate of 115.7 months and 102.7 months, respectively.
“Our group published research demonstrating that hormonal therapy showed promise in the recurrent setting, with most patients responding or having stable disease,” said David Gershenson, MD.